An analog of aromatic cytokinins, the 2,6,9-trisubstituted purine derivative bohemine, was applied to cultures of mouse hybridoma cells in order to analyze its capacity of suppressing cell growth and maintaining or enhancing the production of monoclonal antibody. Addition of bohemine at concentrations in the range of1-10 muM resulted in a short-term arrest of growth and of monoclonal antibody production. The short-term suppression of cell functions was followed by a significant temporary increase of specific growth rate and of specific production rate. The steady-state viable cell density values, found in semicontinuous cultures, showed a certain stimulation of cell growth in the range of micromolar concentrations of bohemine, and inhibition of growth at 10 and 30 muM concentrations. The profiles of cell cycle phases indicated that hybridoma cells are retarded both at the G(1)/S boundary and at the G(2)/M boundary, depending on bohemine concentration. The existence of the sequence of events,from suppression to stimulation, suggests that bohemine probably modulates more than one regulatory pathway in the cell.

Laboratory of Growth Regulators Institute of Experimental Botany Academy of Sciences of the Czech Republic 10227 Praha 10 Czech Republic

Zobrazit více v PubMed

Alberio R, Kubelka M, Zakhartchenko V, Hajdúch M, Wolf E, Motlík J. Activation of bovine oocytes by specific inhibition of cyclin-dependent kinases. Mol Reprod Dev. 2000;55:422–432. doi: 10.1002/(SICI)1098-2795(200004)55:4<422::AID-MRD10>3.0.CO;2-C. PubMed DOI

Chang Y-T, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol. 1999;6:361–375. doi: 10.1016/S1074-5521(99)80048-9. PubMed DOI

Chmela Z, Veselý J, Lemr K, Rypka M, Hanuš J, Havlíček L, Kryštof V, Michnová L, Fuksová K, Lukeš J. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclindependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route. Drug Metabol Disp. 2001;vn29:326–334. PubMed

De Azevedo WF, Leclerc S, Meijer L, Havlíček L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997;243:318–326. PubMed

Fenge C, Fraune E, Freitag R, Scheper T, Schügerl K. On-line monitoring of monoclonal antibody formation in highdensity perfusion culture using FIA. Cytotechnology. 1991;6:55–63. doi: 10.1007/BF00353703. PubMed DOI

Franěk F, Holý A, Votruba I, Eckschlager T. Modulation of cell cycle progression and of antibody production in mouse hybridomas by a nucleotide analogue. Cytotechnology. 1998;28:65–72. doi: 10.1023/A:1008017328061. PubMed DOI PMC

Frančk F, Šrámková K. Cell suicide in starving hybridoma culture: Survival-signal effect of some amino acids. Cytotechnology. 1996;21:81–89. doi: 10.1007/BF00364839. PubMed DOI

Frančk F, Vomastek T, Dolníková J. Fragmented DNA and apoptotic bodies document the programmed way of cell death in hybridoma cultures. Cytotechnology. 1992;9:117–123. PubMed

Fussenegger M, Mazur X, Bailey JE. A novel cytostatic process enhances the productivity of Chinese hamster ovary cells. Biotechnol Bioeng. 1997;55:927–939. doi: 10.1002/(SICI)1097-0290(19970920)55:6<927::AID-BIT10>3.0.CO;2-4. PubMed DOI

Hajdúch M, Havlíček L, Veselý J, Novotný R, Mihál V, Strnad M. Synthetic cyclin-dependent kinase inhibitors. New generation of potent anti-cancer drugs. In: Pieters R, Veerman A, Kaspers GJL, editors. Advances in Experimental Medicine and Biology. Plenum Press: New York; 1999. pp. 341–353. PubMed

Havlíček L, Hanuš J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. Med Chem. 1997;40:408–412. doi: 10.1021/jm960666x. PubMed DOI

Holý A. Isopolar phosphorus-modified nucleotide analogues. In: DeClercq E, editor. Advances in Antiviral Drug Design. Greenwich, CT: JAI Press, Inc.; 1994. pp. 179–232.

Kirchhoff S, Kröger A, Cruz H, Tümmler M, Schäper F, Köster M, Hauser H. Regulation of cell growth by IRF-1 in BHK-21 cells. Cytotechnology. 1996;22:147–156. doi: 10.1007/BF00353934. PubMed DOI

KováŐová H, Hajdúch M, Kořínková G, Halada P, Krupičková S, Gouldsworthy A, Zhelev N, Strnad M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclindependent kinase inhibitor, bohemine. Electrophoresis. 2000;21:3757–3764. doi: 10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X. PubMed DOI

Kramata P, Votruba I, Otová B, Holý A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol. 1996;49:1005–1011. PubMed

Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 1982;42:65–82. PubMed

Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclindependent kinase inhibitors. Bioorg Med Chem. 1999;7:1281–1293. doi: 10.1016/S0968-0896(99)00064-4. PubMed DOI

Legraverend M, Tunnah P., Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Cyclin-dependent kinase inhibition by new C-alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J Med Chem. 2000;43:1282–1292. doi: 10.1021/jm9911130. PubMed DOI

Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, Inagaki M, Delcros J-G, Moulinoux J-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997;243:527–536. doi: 10.1111/j.1432-1033.1997.t01-2-00527.x. PubMed DOI

Otyepka M. K., Havlíček L, Siglerová V, Strnad M, Koča J. Docking-based development of purine-like inhibitors of cyclin-dependent kinase - 2. J Med Chem. 2000;43:2506–2513. doi: 10.1021/jm990506w. PubMed DOI

Pines J. Cyclines and cyclin-dependent kinases: A biochemical view. Biochem J. 1995;308:697–711. PubMed PMC

Rosania GR, Chang YT, Perez O, Sutherlin D, Dong H, Lockhart DJ, Schultz PG. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nature Biotechnol. 2000;18:304–308. doi: 10.1038/73753. PubMed DOI

Suzuki E, Ollis DF. Enhanced antibody production at slowed growth rates: Experimental demonstration and a structured model. Biotechnol Prog. 1990;6:231–236. doi: 10.1021/bp00003a013. PubMed DOI

Suzuki E, Takahashi K, Ollis DF, et al. A simple structured model predicted positively-, negatively-, or non-growth associated antibody production rate depending on culture conditions. In: Murakami H, et al., editors. Animal Cell Technology: Basic and Applied Aspects. Dordrecht: Kluwer Academic Publishers; 1992. pp. 375–381.

Takahashi K, Terada S, Ueda H, Makishima F, Suzuki E. Growth rate suppression of cultured animal cells enhances protein productivity. Cytotechnology. 1994;15:54–64. doi: 10.1007/BF00762379. PubMed DOI

Veselý J, Havlíček L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994;224:771–786. doi: 10.1111/j.1432-1033.1994.00771.x. PubMed DOI